Cian Healthcare Announces 23rd AGM, Auditor Change, and New ESOS Plan

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorAarav Shah|Published at:
Cian Healthcare Announces 23rd AGM, Auditor Change, and New ESOS Plan

Cian Healthcare Ltd has scheduled its 23rd AGM for September 29, 2026. Key agenda items include the appointment of M/s Rasool Singhal & Co. as new statutory auditors following the resignation of M/s S S R C A & Co., and the introduction of an Employee Stock Option Scheme (ESOS 2026) involving up to 1 crore equity shares.

Cian Healthcare Sets 23rd AGM Agenda

  • AGM Date: September 29, 2026
  • New ESOS Plan: Up to 1 crore options

Reader Takeaway: Auditor transition and a new 10-million share ESOS plan mark the key governance and incentive updates.

What just happened

Cian Healthcare Ltd has released its notice for the 23rd Annual General Meeting (AGM) to be held virtually on September 29, 2026. The meeting will address several critical corporate matters, including the appointment of new statutory auditors and the approval of a significant employee incentive framework.

Why this matters

The company is formalizing a leadership transition in its audit function. Following the resignation of M/s S S R C A & Co. on August 27, 2026, due to prior commitments, the Board has moved to appoint M/s Rasool Singhal & Co. for a five-year tenure. Additionally, the proposal for the Employee Stock Option Scheme (ESOS 2026) signals a shift toward equity-linked performance incentives for staff and eligible directors.

Corporate Action Details

The proposed ESOS 2026 aims to issue up to 1,00,00,000 options. Each option is convertible into one fully paid-up equity share with a face value of INR 10. The vesting period is set between one and four years from the grant date, with an exercise window of five years post-vesting. This scheme includes employees of the company as well as its subsidiaries and associate entities.

What changes now

Shareholders are invited to vote on these proposals via video conferencing. The re-appointment of Mr. Pradeep Kumar Jain as a Non-Executive Director is also on the ballot. If approved, the ESOS plan could lead to future equity dilution, which is a standard consideration for existing shareholders regarding earnings per share.

What to track next

Investors should monitor the outcome of the shareholder vote at the AGM and the subsequent timeline for the grant of options under the new ESOS 2026 framework.

Disclaimer: This article is published for informational purposes only. This is not a buy sell recommendation.